Resistance to doxorubicin in tumor cells in vitro and in vivo after pretreatment with verapamil.
Sarcoma 180 (S180) cells pretreated with verapamil increase their resistance to doxorubicin in vitro. This result could be confirmed by in vivo experiments using P388 cells. The mechanism for this resistance is different from the P-glycoprotein-mediated mechanism characteristic for multidrug-resistant cells.
Donenko
F V
FV
Institute of Clinical Oncology, All-Union Cancer Research Center, Moscow, USSR.
Efferth
T
T
Mattern
J
J
Moroz
L V
LV
Volm
M
M
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000818:Animals; D004317:Doxorubicin / Q000494:pharmacology*; D004351:Drug Resistance; D007941:Leukemia P388 / Q000188:drug therapy; D008297:Male; D008562:Membrane Glycoproteins / Q000096:biosynthesis; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D012510:Sarcoma 180 / Q000188:drug therapy*; D013997:Time Factors; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014700:Verapamil / Q000494:pharmacology*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D008562:Membrane Glycoproteins; D004317:Doxorubicin; D014700:Verapamil